European commission approves kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat children with cystic fibrosis ages 6 to 11 years

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european commission has granted approval for the label extension of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients ages 6 through 11 years old who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene. “we are delighted that kaftrio (ivacaftor/tezacaftor/
VRTX Ratings Summary
VRTX Quant Ranking